PIPR:NYSEPiper Sandler Companies Analysis
Data as of 2026-07-27 - not real-time
$76.71
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Piper Sandler (PIPR) trades at $76.71, comfortably above its 20‑day SMA (74.48) but still below the 50‑day (77.21) and 200‑day (81.82) averages, signaling a short‑term pullback within a longer‑term uptrend. Revenue growth of 32.8% and ultra‑high gross margins (91%) underpin a robust earnings profile, while ROE of 22% and ROA of 16% demonstrate efficient capital use. Technical indicators are mixed: RSI sits near neutral (51.8), MACD histogram is positive (0.45) and flagged bullish, yet volume is decreasing and the 30‑day volatility is elevated at 36%, reflecting a cautious market tone.
Analyst sentiment remains positive (Buy) with a median price target of $88.75, implying ~15% upside, and the DCF‑derived fair value of $191.7 suggests the stock is markedly undervalued on a discounted cash‑flow basis. The dividend yield of 0.95% is modest but the payout ratio of 17% indicates a sustainable dividend supported by ample cash ($830M) and a net‑cash balance after debt.
Overall, the company’s strong growth trajectory, solid profitability, and attractive valuation relative to peers and intrinsic models outweigh the near‑term bearish technical bias and heightened market volatility.
Analyst sentiment remains positive (Buy) with a median price target of $88.75, implying ~15% upside, and the DCF‑derived fair value of $191.7 suggests the stock is markedly undervalued on a discounted cash‑flow basis. The dividend yield of 0.95% is modest but the payout ratio of 17% indicates a sustainable dividend supported by ample cash ($830M) and a net‑cash balance after debt.
Overall, the company’s strong growth trajectory, solid profitability, and attractive valuation relative to peers and intrinsic models outweigh the near‑term bearish technical bias and heightened market volatility.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Bullish MACD histogram indicating near‑term momentum
- Support level around $70.27 providing downside cushion
- Current price still below analyst median target, offering ~15% upside
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Strong revenue growth (33%) and high operating margins
- Forward P/E of 13.7 suggesting attractive valuation relative to earnings
- Sustainable dividend with low payout ratio and strong cash position
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Long‑term DCF fair value far above current price, indicating substantial undervaluation
- Consistent high ROE and ROA reflecting durable competitive advantage
- Net‑cash balance and low debt‑to‑equity risk supporting future strategic investments
Key Metrics & Analysis
Financial Health
Revenue Growth32.80%
Profit Margin13.97%
P/E Ratio19.4
ROE22.17%
ROA16.48%
Debt/Equity7.33
P/B Ratio3.9
Op. Cash Flow$502.1M
Industry P/E18.0
Technical Analysis
TrendBearish
RSI51.8
Support$70.27
Resistance$78.65
MA 20$74.48
MA 50$77.21
MA 200$81.82
MACDBullish
VolumeDecreasing
Fear & Greed Index87.79
Valuation
Fair Value$191.69
Target Price$88.13
Upside/Downside14.88%
GradeUndervalued
TypeGrowth
Dividend Yield0.95%
Risk Assessment
Beta1.39
Volatility36.13%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.